Advertisement
Singapore markets open in 3 hours 27 minutes

  • Straits Times Index

    3,332.80
    -10.55 (-0.32%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • Dow

    39,118.86
    -45.24 (-0.12%)
     

  • Nasdaq

    17,732.60
    -126.10 (-0.71%)
     

  • Bitcoin USD

    61,848.08
    +896.44 (+1.47%)
     

  • CMC Crypto 200

    1,287.30
    +3.47 (+0.27%)
     

  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     

  • Gold

    2,336.90
    -2.70 (-0.12%)
     

  • Crude Oil

    81.46
    -0.08 (-0.10%)
     

  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     

  • Nikkei

    39,583.08
    +241.58 (+0.61%)
     

  • Hang Seng

    17,718.61
    +2.11 (+0.01%)
     

  • FTSE Bursa Malaysia

    1,590.09
    +5.15 (+0.32%)
     

  • Jakarta Composite Index

    7,063.58
    -6,967.95 (-49.66%)
     

  • PSE Index

    6,411.91
    +21.33 (+0.33%)
     

What's Going On With Merck Stock On Friday?

Vandana Singh
·2-min read
What's Going On With Merck Stock On Friday?
What's Going On With Merck Stock On Friday?

On Thursday, the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend Merck & Co Inc’s (NYSE:MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for adults 65 years of age and older. It is also commonly known as the pneumonia vaccine.

Specifically, the ACIP voted to recommend a single dose of Capvaxive for:

  • Adults 65 years and older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.

  • Adults 19-64 years of age with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.

  • Adults 19 years and older who have started their pneumococcal vaccine series with PCV13 (pneumococcal 13-valent conjugate vaccine) but have not received all recommended PPSV23 (pneumococcal 23-valent polysaccharide vaccine) doses.

ADVERTISEMENT

Additionally, shared clinical decision-making is recommended regarding the use of a supplemental dose of Capvaxive for adults 65 years and older who have completed their vaccine series with both PCV13 and PPSV23.

Friday, Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended the approval of Winrevair (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies for adult PAH patients with World Health Organization Functional Class II to III, to improve exercise capacity.

The European Commission (EC) will now review the CHMP recommendation. The EC’s decision on Winrevair’s marketing authorization application is expected in the third quarter of 2024.

The CHMP recommendation is based on data from the Phase 3 STELLAR trial of Winrevair on top of background PAH therapy compared to background therapy alone.

Winrevair demonstrated a statistically significant and clinically meaningful improvement in the 6-minute walk distance, the study’s primary endpoint, and on multiple important secondary outcome measures, including reducing the risk of death from any cause or PAH clinical worsening events.

Also Read: FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug.

Price Action: MRK shares were trading higher by 0.13% at $129.99 premarket at the last check on Friday.

Photo via Unsplash

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article What's Going On With Merck Stock On Friday? originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.